Ann: Second Supplementary Scheme Booklet, page-6

Page 3, Section 1:

the Bridging Loan (defined below) entered into between ResApp and Pfizer Australia to
provide for ResApp’s short-term working capital needs during the extended Scheme period;
.....
Importantly, ResApp Shareholders are advised that if the Scheme is not implemented by
23 September 2022, the current indicative Implementation Date, and the Scheme Implementation
Deed is terminated, ResApp will be required to immediately secure external funding to repay the
Bridging Loan (defined below) and to continue to fund ordinary further business activities.

The Board believes it will be able to raise the required funds on the equity capital market, albeit
potentially at a significant discount to the prevailing share price, and in this regard notes that it has
its full placement capacity under Listing Rule 7.1 available to facilitate a prompt placement of Shares
to one or more third parties. The Board is also investigating alternative financing arrangements,
including the borrowing of money against the future receipt of any tax rebates.